Calmactin Approval Status
Calmactin (cilansetron) is a 5-HT3 receptor antagonist in development for the treatment of irritable bowel syndrome with diarrhea predominance (IBS-D).
In April 2005, Solvay Pharmaceuticals, Inc. announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Calmactin (cilansetron) had not been approved.
Development Status and FDA Approval Process for Calmactin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.